Introduction:

After COVID-19, emerged after much research a supply of vaccines approved worldwide, these vaccines must confer effective protection for a prolonged time, possess a good safety profile, be affordable and be easily accessible to all, a challenge difficult to achieve due to the time and characteristics of the virus.

Objective:

to determine the concentration of neutralizing antibodies post vaccination in a population of Blood Bank workers;

Material and methods:

A prospective, descriptive, observational, cross-sectional study was carried out, taking as study population all the Blood Bank personnel, among men and women with an age range between 26 and 72 years old. the increase of Neutralizing Antibodies was evaluated after inoculation of the second dose of Sinopharm on 05/19/21, then the amount of antibodies generated was measured on 10/20/21 prior to the third booster dose of Astrazeneca, evaluating again 35 days after the third dose on 12/02/2021 and finally evaluating these levels on 01/26/2022. The technique used was the EUROIMMUN Anti-SARS-CoV-2 S1 ELISA.

Results and conclusions:

It can be verified that the concentration of N.A. produced by vaccination from Sinopharm and the booster with Astrazeneca favored that these antibodies remained high over time (322 days after the first dose) reaching 80% of the maximum concentration in the final reading. We conclude that with each booster of anti SARS CoV 2 vaccine, the titer of N.A. rises significantly, which is why we consider important in our country a fourth dose as a preventive and immunity method.

        · resumen en Español     · texto en Español     · Español ( pdf )